Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status
نویسندگان
چکیده
منابع مشابه
Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
Anaplastic lymphoma kinase (ALK) rearrangement is most commonly observed in lung adenocarcinoma in a subset of lung cancer. Large cell neuroendocrine carcinoma (LCNEC) harboring an ALK rearrangement is very rare. Based on the findings from a transbronchial lung biopsy, a 75-year-old non-smoking woman was diagnosed with LCNEC with multiple liver and bone metastases. After seven cycles of cytotox...
متن کاملAlectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
Alectinib, a novel alternative anaplastic lymphoma kinase (ALK) inhibitor, is highly effective against ALK-positive non-small cell lung cancer (NSCLC) and is well tolerated. Molecular targeted agents generally have little contribution to alopecia. We encountered a case of alopecia that developed gradually over 2 months after initiation of alectinib administration for the treatment of ALK-positi...
متن کاملCeritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma.
The anaplastic lymphoma kinase (ALK) gene is expressed in.50% of anaplastic large-cell lymphomas (ALCLs). Although most patients withALK-positiveALCL respondwell to anthracycline-based chemotherapy, relapses do occur (5-year failure-free survival 60%) and require salvage therapy, generally with poor outcomes. Autologous stem cell transplant is an option in the salvage setting, but not all patie...
متن کاملAlectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
BACKGROUND Alectinib is an oral drug developed for the treatment of patients with fusion gene encoding echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK)-rearranged non-small cell lung cancer (NSCLC). Here, we present the case of a patient treated with alectinib who developed a hypersensitivity reaction with successful rechallenge treatment. CASE PRESENTATI...
متن کاملCost-Effectiveness Of Ceritinib In Previously Treated Patients With Crizotinib In Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small Cell Lung Cancer In Canada.
• The model consists of 3 mutually exclusive health states: stable disease (SD), progressive disease (PD), and death (D) (Figure 1). At the start of the treatment, it was assumed that all patients enter the stable disease state. The proportion of patients in the progressive disease state at each cycle was calculated as the difference between the proportion of patients who died and the proportio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: OncoTargets and Therapy
سال: 2018
ISSN: 1178-6930
DOI: 10.2147/ott.s186213